At Hudson Valley Ketamine Lounge, we’re always exploring safe, evidence-informed ways to enhance our patients’ healing journeys. Ketamine therapy has already transformed lives by providing rapid relief for treatment-resistant depression, PTSD, and chronic pain. Now, we’re proud to integrate NAD+ (nicotinamide adenine dinucleotide) into our IV protocols—an innovative pairing that supports both the body and the brain. https://hvketamine.com
Why NAD+ Matters
NAD+ is often called the “spark plug” of cellular energy. It fuels mitochondrial function, DNA repair, and anti-inflammatory pathways that keep our cells resilient. Levels of NAD+ naturally decline with age, stress, and chronic illness—exactly the circumstances that often accompany mood disorders and chronic pain.
By replenishing NAD+ directly through IV therapy, patients may experience:
- Reduced inflammation and oxidative stress
- Improved cellular repair and recovery
- Enhanced brain resilience and energy metabolism
These benefits align beautifully with ketamine’s mechanism of action, which promotes neuroplasticity and new connections in the brain.
The Inflammation Connection: Pain and NAD+
Chronic pain is more than a sensation—it’s often fueled by a cycle of inflammation in the nervous system and tissues. Research suggests NAD+ plays a role in calming overactive immune pathways, reducing oxidative stress, and supporting tissue repair.
When combined with ketamine, which is already known to reset pain signaling in the brain and spinal cord, NAD⁺ may help:
- Ease inflammatory pain conditions (such as fibromyalgia or neuropathic pain)
- Support recovery from central sensitization (“pain hypersensitivity”)
- Promote longer-lasting relief and overall resilience
While ketamine provides rapid recalibration of the nervous system, NAD⁺ supports the foundation of cellular health—together creating a comprehensive approach to pain management.
What Patients Can Expect
At Hudson Valley Ketamine Lounge, NAD⁺ can be offered alongside ketamine infusions as an optional wellness add-on. Our providers tailor each session to your needs, ensuring safety, comfort, and personalized dosing.
Patients who receive NAD⁺ often describe:
- A sense of increased clarity and focus
- Improved energy and reduced fatigue
- Decreased “inflammatory flares” or pain sensitivity
Most importantly, NAD⁺ is not a replacement for ketamine—it’s a synergistic partner, working in the background to help the body heal while the mind experiences ketamine’s transformative effects.
Our Commitment to Innovation and Care
At HVKL, we believe in treating the whole person, not just the diagnosis. By integrating NAD⁺ into select IV protocols, we’re offering patients a chance to optimize both the short-term relief of ketamine and the long-term support of cellular health.
We’re also committed to transparency: while studies on NAD⁺ in psychiatry and pain management are still developing, its role in reducing inflammation and supporting energy metabolism makes it a natural and exciting partner for ketamine therapy.
Is NAD+ Right for You?
If you’re considering ketamine therapy for chronic pain or mood disorders, ask our team about NAD⁺ integration. Together, we’ll design a treatment plan that supports your body’s healing potential, reduces inflammation, and helps restore balance—inside and out.
References (APA 7)
Berven, H., Alves, G., & Bindoff, L. A. (2023). NR-SAFE: A randomized, double-blind safety trial of high-dose nicotinamide riboside in Parkinson’s disease. Nature Communications, 14, 7927. https://doi.org/10.1038/s41467-023-43514-6
Kang, M. J. Y., Voleti, B., Haj-Mirzaian, A., & Hashmi, J. A. (2022). The mechanisms behind rapid antidepressant effects of ketamine: A systematic review. Frontiers in Psychiatry, 13, 860882. https://doi.org/10.3389/fpsyt.2022.860882
Radenkovic, D., Reason, B., & Verdin, E. (2020). Clinical evidence for targeting NAD therapeutically. Pharmaceuticals, 13(9), 247. https://dohttps://doi.org/10.3390/ph13090247i.org/10.3390/ph13090247
Riggs, L. M., & Gould, T. D. (2021). Ketamine and the future of rapid-acting antidepressants. Annual Review of Clinical Psychology, 17, 207–231. https://doi.org/10.1146/annurev-clinpsy-072120-014126
Wang, X., Li, X., Yin, J., Zhao, B., Wang, H., & Li, Y. (2023). Neuroprotection of NAD⁺ and NBP against ischemia/reperfusion injury: Synergistic effects via SIRT1/SIRT3. Frontiers in Pharmacology, 14, 1096533. https://doi.org/10.3389/fphar.2023.1096533